Lantern Pharma. has filed a patent application for markers that can determine the sensitivity of a cancer patient to an anti-cancer agent, such as illudins or illudin analogs. The method involves determining the expression level of biomarkers, genes associated with DNA repair, or their transcription levels. This could help determine if the patient’s cancer will respond to the anti-cancer agent. GlobalData’s report on Lantern Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Lantern Pharma, Cancer treatment biomarkers was a key innovation area identified from patents. Lantern Pharma's grant share as of September 2023 was 22%. Grant share is based on the ratio of number of grants to total number of patents.
Method for determining cancer sensitivity to illudin or illudin analogs
A recently filed patent (Publication Number: US20230304104A1) describes a method for determining the sensitivity of a cancer to an anti-cancer agent. The method involves analyzing the expression levels of biomarkers and genes associated with DNA repair, as well as the transcription levels of these genes. The anti-cancer agent in question is either illudin or an illudin analog.
The patent claims specify various aspects of the method. For example, claim 4 states that a reduced expression or transcription level compared to a standard or control sample indicates a sensitivity of the cancer to the anti-cancer agent. Claim 6 mentions that the method can be applied to solid tumors, including those in the breast, central nervous system, colon, skin, lung, ovary, prostate, or kidney. Claim 11 lists specific genes associated with DNA repair that can be analyzed, such as BRCA1, BRCA2, ATM, ATR, ERCC2, ERCC3, ERCC4, ERCC5, ERCC6, FANCD2, RAD51, or PALB2. Similarly, claim 12 provides examples of biomarkers that can be examined, including RPA1, FANCE, FANCL, ERCC8/CSA, BRIP1, FANCF, MRE11A, BLM, ERCC3/XPB, FANCM, FANCB, FANCE, CHEK1, FANCI, ATM, ERCC4/XPG, ERCC6/CSB, CHEK2, ERCC2/XPD, or ERCC3 genes.
The patent also describes a method for screening an anti-cancer agent for use in the treatment of cancer. This involves determining changes in expression levels of biomarkers and genes associated with DNA repair, as well as transcription levels, in a sample taken from a subject after exposure to the anti-cancer agent. A decrease in expression or transcription level indicates sensitivity to the anti-cancer agent.
Furthermore, the patent includes a method for treating cancer by administering an effective amount of an anti-cancer agent to a subject with reduced expression levels of biomarkers or genes associated with DNA repair. The patent specifies that the anti-cancer agent can be illudin or an illudin analog.
Overall, this patent presents a method for determining the sensitivity of cancer to an anti-cancer agent based on the analysis of biomarkers and genes associated with DNA repair. The method can be used for screening potential anti-cancer agents and for treating cancer in patients with specific expression patterns. The patent also mentions the possibility of using a kit that includes reagents, standards, and instructions for performing the method.
To know more about GlobalData’s detailed insights on Lantern Pharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
